Rasagiline Mesylate Patent Expiration
Rasagiline Mesylate is Used for managing the symptoms of Parkinson's disease. It was first introduced by Teva Neuroscience Inc
Rasagiline Mesylate Patents
Given below is the list of patents protecting Rasagiline Mesylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Azilect | US7815942 | Rasagiline formulations of improved content uniformity | Aug 27, 2027 | Teva |
| Azilect | US7572834 | Rasagiline formulations and processes for their preparation | Dec 05, 2026 | Teva |
| Azilect | US5453446 | Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease. |
Feb 07, 2017
(Expired) | Teva |
| Azilect | US6126968 | Stable compositions containing N-propargyl-1-aminoindan |
Sep 18, 2016
(Expired) | Teva |
| Azilect | US5532415 | R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof |
Jul 02, 2013
(Expired) | Teva |
Rasagiline Mesylate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List